Stroke: Keeping your world separate from mine

Dr Andrew Wong MBBS PhD FRACP Director, Neurology and Stroke

Royal Brisbane and Women's Hospital August 2014



Great state. Great opportunity.

Disclosures

Speakers honoraria & Sponsorship

(flights, accommodation, conference registration)

Boehringer Ingelheim : Alteplase (tPA), Asasantin, Pradaxa Bayer : Xarelto

Pfizer : Eliquis

BMS (Bristol-Myers Squibb) : Eliquis

Astra Zenica : Brilinta

Covidien : Sequential Compression Devices


Concepts

• Primary Prevention vs. Secondary prevention

- Absolute risk
 - Per 1000 patient years; or 50 people for 20y
 - Your chance per year
- Relative risk
 - Your chance compared with another's chance



What is a "Stroke"



Sensory Function

Hand Hip skills Trunk Leg Trunk

Neck Arm Arm Fingers Hand

Face

Hand

Face

Emotions

Speech

Smell

Language

Hearing

2. 11 2

Vision

Posture Balance Coordination

1. Signs and symptoms of stroke

It's only weakness numbness difficulty speaking dizziness loss of vision a headache difficulty swallowing

It's only a stroke.

Weakness, Numbress, Difficulty Speaking, Dizziness, Loss of Vision, Headache and Difficulty Swalkowing are all signs of stroke. If you experience the signs of stroke seek immediate medical attention. For free information call the National Stroke Foundation on 1800 787 883 or visit www.strokefoundation.com.au



The *FAST* campaign – a public education tool in use internationally



D



KEY INFORMATION ON HOW TO RECOGNISE THE



FACE- Can they smile? Does one side droop?

ARM– Can they lift both arms? Is one weak?

SPEECH- Is their speech slurred or muddled?

TEST- Check for all three symptoms.

If you see these signs call 999 FAST.

If you recognise the signs of STROKE act Arm Facial Speech Time to weakness weakness difficulty act fast Call 000 Is it a Stroke? Act FAST. Call 111.

 Face - SMILE
 Arms - RAISE BOTH ARMS

 (is one side droopy?)
 (is one side weak?)

Speech - SPEAK A SIMPLE SENTENCE (slurred? unable to?)




Pub Charity.

Stroke is a medical emergency



What is your stroke 'risk'



http://strokefoundation.com.au/healthprofessionals/tools-and-resources/facts-and-figuresabout-stroke/

Royal Brisbane and Women's Hospital Metro North Health Service District

Primary Prevention

Guidelines for the assessment of

Absolute cardiovascular disease **risk**

http://www.strokefoundation.com.au/general-practice

21.05 - Westmakey 16 November 20

Australian absolute cardiovascular disease risk calculator

Systelic blood pr Smoking status		arrity 0 0		
Total cholesterol				
HDL cholesterol Diabeter	and the second s	ia o		
		io Olinhnawn		
	-			
abie of the Nationa		nie Prosettor Al	Station	

Coppright C 2018 Rational Taxoniar Diagona Prevartion Alliance (NVDPR) (Decisives


What happens after a stroke?


than major bleeding (0.60); however, moderate stroke (0.09) was rated to be about as bad as death (0), and major stroke (-0.36) was considered to be worse than death.

How we manage stroke in Australia, AIHW 06

LaHaye 2014

What does a stroke look like?





What does a stroke do to a person?

How can you avoid having a stroke?





EMBARGOED UNTIL Monday 5th May 2014 (00'01 AEST)

New results on the world's largest study on stroke risk factors presented at World Congress of Cardiology

Ten easily measurable and modifiable risk factors could explain 90 per cent of the risk of stroke in all regions

Melbourne (Monday 5 May) - Preliminary findings from the completed INTERSTROKE study presented for the first time today at the World Heart Federation's World Congress of Cardiology reported new and important results. INTERSTROKE evaluates the importance of risk factors for stroke and the first phase showed that 10 known risk factors are associated with about 90% of strokes. The new preliminary results confirm these findings in larger patient populations and further to the first phase, demonstrate an overall consistency in the collective importance of these risk factors around the world. This reinforces the fact that action is needed worldwide to control those 10 risk factors - hypertension, lipids, smoking, physical inactivity, abdominal obesity, cardiac causes, diet, alcohol, diabetes mellitus and psychosocial factors. Of these, hypertension is the most important.


INTERSTROKE is the largest international study ever to evaluate the importance of both established and novel risk factors for stroke, which affects millions of people worldwide. Completed in March 2014, the much anticipated study led by Dr Martin O'Donnell (Population Health Research Institute, McMaster University and HRB-Clinical Research Facility, NUI Galway, Ireland) and Dr Salim Yusuf (Population Health Research Institute, McMaster University, Canada) included over 27,000 patients from 32 countries across the world. It involved an international collaboration of committed stroke physicians cardiologists and researchers, keen to build on the landmark INTERHEART study led by Dr Yusuf, which looked at modifiable risk factors for heart attacks.

"The INTERSTROKE study represents an important resource to progress our understanding of the causes of stroke, both in estimating the contribution of known modifiable risk factors for stroke and in identifying and clarifying the role of new ones, such as genetics," said Dr O'Donnell. "These results are the completion of eight years of work and, on behalf of the INTERSTROKE group, we are delighted to share them with colleagues from around the world today in this preliminary analysis. We especially look forward to sharing our full data results later this year and continuing to collaborate with colleagues globally to fight the battle against stroke, which is a leading cause of death and disability worldwide."

Stroke kills nearly six million people per year and is the second leading cause of disability globally after dementia. For more information about stroke, its symptoms and causes go to: www.world-heart-federation.org/cardiovascular-health/stroke


For more information: WCC Press Office: Rosie Ireland on 44 7590 228701 Tara Farrell on 44 7769 362880 wcc@webershandwick.com

High blood pressure (Hypertension) causes both ischaemic and haemorrhagic stroke



Cigarettes increase stroke risk

Diet, cholesterol





The Heart Foundation Tick has been helping Australians make healthier food choices for 25 years. The easily recognisable front-of-pack logo highlights healthier food choices without the need to scrutinise nutrition information panels and ingredient lists.

As an independent not-for-profit program. Tick works with food manufacturers to make foods healthier. We do this by setting strict nutrient standards for foods which manufacturers are encouraged to meet by changing their product recipes.


Once a food has met these standards, the manufacturer can apply to carry the Tick logo. This means that all Australians when shopping can easily identify foods that are lower in saturated fat, trans fat, sodium (salt), kilojoules (energy), and which contain more beneficial ingredients like fibre, calcium, wholegrains and vegetables.


The Tick also appears on a range of healthy, everyday foods like bread, reduced fat milk, frozen vegetables, pasta, rice, breakfast cereals and, lean meat and canned fish. There are more than 2.000 products approved to use the Tick.

Exercise

Regular involvement in moderate or strenuous exercise 4h or more per week was associated with a 30% risk reduction

Abdominal obesity





Cardiac causes


- Atrial Fibrillation or Flutter
- Previous myocardial infarction (heart attack)
- Rheumatic heart disease
- Prosthetic heart valve

If you don't know what these things are, that's probably a good thing. If you do – consult your doctor.



Diabetes






Psychosocial factors

- Depression
- Stress
- Locus of control
- Life events

These are difficult risk factors to 'treat', but it's worth doing if possible.

Alcohol





1-30 drinks per month = 20% less ischaemic stroke

Interstroke 2010

Other things that affect stroke risk

J Am Coll Cardiol, 2010; 55:2878-2886, doi:10.1016/j.jacc.2010.04.003 (Published online 27 May 2010). © 2010 by the American College of Cardiology Foundation

EXPERT CONSENSUS DOCUMENT

Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes

American Diabetes Association American Heart Association American College of Cardiology Foundation, Royal Brisbane and Women's Hospital Metro North Health Service District

Aspirin

diabetes, including any sex-specific differences. For now, we recommend the following:

 Low-dose (75 to 162 mg/day) aspirin use for prevention is reasonable for adults with diabetes and no previous history of vascular disease who are at increased CVD risk (10 year risk of CVD events over 10%) and who are not at increased risk for bleeding (based on a history of previous gastrointestinal bleeding or peptic ulcer disease or concurrent use of other medications that increase bleeding risk, such as NSAIDS or warfarin). Those adults with diabetes at increased CVD risk include most men over age 50 years and women over age 60 years who have one or more of the following additional major risk factors: smoking, hypertension, dyslipidemia, family history of premature CVD, and albuminuria. (ACCF/AHA Class IIa, Level of Evidence: B) (ADA Level of Evidence: C)

Aspirin should not be recommended for CVD prevention for adults with diabetes at low CVD risk (men under age 50 years and women under 60 years with no major additional CVD risk factors; 10-year CVD risk under 5%) as the potential adverse effects from bleeding offset the potential benefits. (ACCF/AHA Class III, Level of Evidence: C) (ADA Level of Evidence: C)
Low-dose (75 to 162 mg/day) aspirin use for prevention might be considered for those with diabetes at intermediate CVD risk (younger patients with one or more risk factors, or older patients with no risk factors, or patients with 10-year CVD risk of 5% to 10%) until further research is available. (ACCF/AHA Class IIb, Level of Evidence: C) (ADA Level of Evidence: E)

Hormone Replacement Therapy

Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women

Principal Results From the Women's Health Initiative Randomized Controlled Trial

(*Prempro/Premia 2.5*) Relative Risk: 1.41 (95% CI 1.07-1.85) Absolute *Risk*: + 0.8 strokes per 1000 person years

JAMA 2002

Hormone Replacement Therapy

A CLINICAL TRIAL OF ESTROGEN-REPLACEMENT THERAPY AFTER ISCHEMIC STROKE

CATHERINE M. VISCOLI, PH.D., LAWRENCE M. BRASS, M.D., WALTER N. KERNAN, M.D., PHILIP M. SARREL, M.D., SAMY SUISSA, PH.D., AND RALPH I. HORWITZ, M.D.

(Estrace/Estrofem) Relative Risk: 2.90 (95% CI 0.9-9.0) Absolute Risk: ? +9 strokes per 1000 person years (NS)

NEJM 2001

Hormone Replacement Therapy

There is (probably) a small increase in the risk of stroke with hormone replacement therapy, but the background rate is quite low

Therefore the likelihood of any one person having a stroke due to HRT is very low

(Under 1:100 p.a. after a stroke Under 1:1000 p.a. with no stroke history)

The Oral Contraceptive Pill

About a million Australian women take the OCP

(e.g. Yaz, Yasmin, Diane) Relative Risk: 1.93 (95% CI 1.35-2.74); controlled for smoking and BP Absolute Risk: +.04 strokes per 1000 person years

This equates to about 40 extra strokes per year in all of Australia.

1 in 24 000 per year

The Oral Contraceptive Pill

There is a small increase in the risk of stroke with oral contraception with oestrogen, but the background rate is very low

Therefore the likelihood of any one person having a stroke due to the OCP is very low (1:24000 p.a.)

40 strokes

Striking Statistics

- Americans are twice as likely to die from lightning than from a hurricane, tornado or flood.
- The Federal Emergency Management Agency estimates there are 20 deaths and 450 severe injuries from lightning each year in the Australia.

1 in 24 000

odds of winning Saturday Gold Lotto

Saturday Gold Lotto odds effective from Draw 3081, 29 January, 2011.

Division	Required to Win in A Single Game Panel	Odds based on 1 Game*
Division 1	6 winning numbers	8,145,060:1
Division 2	5 winning numbers + 1 or 2 supplementary numbers	678,755:1
Division 3	5 winning numbers	36,689:1
Division 4	4 winning numbers	733:1
Division 5	3 winning numbers + 1 or 2 supplementary numbers	2 <mark>97</mark> :1
Division 6	1 or 2 winning numbers + 2 supplementary numbers	144:1

Migraine

- Men: 1.37 (0.89-2.11)
- Women: 2.08 (1.13-3.84)
- No aura: 1.23 (0.9-1.69)
- With aura: 2.16 (1.53-3.03)
- With aura and smoking: 1.5 (1.1-2.3)
- With aura, smoking and OCP:

10.0 (1.4-73.7)

If you have migraine with aura, do not smoke and do not take the oral contraceptive pill Schurks et al. BMJ 2009

Secondary Prevention

"Blood thinners"

- Aspirin
- Asasantin
- Plavix
- Iscover
- Clopidogrel
- Warfarin
- Eliquis
- Pradaxa
- Rivaroxaban

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

Lancet 2001

	Number	of events		
	Active (n=3051	Placebo) (n=3054)	Favours active	Favours Relative risk placebo reduction (95% CI)
Stroke subtypes				
Fatal or disabling	123	181 -		33% (15 to 46)
Not fatal or disabling	g 201	262		24% (9 to 37)
lschaemic stroke	246	319	-	24% (10 to 35)
Cerebral haemorrha	ge 37	74 🔶	+	50% (26 to 67)
Stroke type unknown	42	51		18% (-24 to 45)
Total stroke	307	420	\diamond	28% (17 to 38)
			N	




Figure 3: Cumulative incidence of stroke among participants assigned active treatment and those assigned placebo

Randomised treatment


Characteristic

PROGRESS Collaborative Group*

	Active (n=3051)	Placebo (n=3054)
Blood pressure and hypertension status		
Mean (SD) systolic blood pressure (mm Hg)	147 (19)	147 (19)
Mean (SD) diastolic blood pressure (mm Hg)	86 (11)	86 (11)
9.5 strokes prevented per 1000 pe	erson-vears (t	able modified)

High-Dose Atorvastatin after Stroke or Transient Ischemic Attack

Variable	Atorvastatin (N=2365)	Placebo (N = 2366)
	no. (%)	
Adverse event		
Any adverse event	2199 (93.0)	2156 (91.1)
Any serious adverse event	988 (41.8)	975 (41.2)
Any adverse event resulting in discontinua- tion of study treatment	415 (17.5)	342 (14.5)
Musculoskeletal adverse events		
Myalgia	129 (5.5)	141 (6.0)
Myopathy	7 (0.3)	7 (0.3)
Rhabdomyolysis†	2 (0.1)	3 (0.1)



NEIM 2006

Average LDL 3.4 mmol/L Average total chol 5.5 mmol/L

Figure 3. Kaplan-Meier Curves for Coronary and Cardiovascular Events.

Results are shown on an intention-to-treat basis with prespecified adjustments for geographic region, entry event (stroke or TIA), time since entry event, sex, and baseline age for the first occurrence of any coronary event (acute coronary event plus coronary revascularization procedure, unstable angina, or angina or ischemia requiring emergency hospitalization) (Panel A), any major coronary event (death from cardiac causes, nonfatal myocardial infarction, resuscitation after cardiac arresty (Panel B), any major cardiovascular event (primary event plus any major coronary event) (Panel C), and any cardiovascular event (any of the former plus clinically significant peripheral vascular disease) (Panel D). HR denotes hazard ratio, and CI confidence interval.

3.9 fatal or nonfatal strokes prevented per 1000 person-years.6.3 major cardiovascular events (stroke, heart attack, death, resuscitation from death)

Emergency treatment The FAST acronym used internationally





If you recognise the signs of STROKE act









Facial weakness

Arm weakness

Speech difficulty

Time to act fast



Is it a Stroke? Act FAST. Call 111.







SIMPLE SENTENCE (slurred? unable to?) Time - Lost time could be lost brain. aet to hospital FAST



Stroke is a medical emeraency



Emergency treatment Time Is Brain—Quantified

Conclusions—Quantitative estimates of the pace of neural circuitry loss in human ischemic stroke emphasize the time urgency of stroke care. The typical patient loses 1.9 million neurons each minute in which stroke is untreated. (Stroke. 2006;37:263-266.)



Emergency treatment





Figure 1: Effect of timing of alteplase treatment on good stroke outcome (mRS 0-1)





EXTEND - 🔼

Extending the time for Thrombolysis in Emergency Neurological Deficits – Intra-Arterial

A randomized controlled trial of intra-arterial reperfusion therapy after standard dose intravenous t-PA within 4.5 hours of stroke onset utilizing dual target imaging selection

Bruce Campbell

Peter Mitchell

Co-PI and Medical Coordinator

Co-PI and Head of Neurointervention

Stephen Davis and Geoffrey Donnan

Co-chairs

ClinicalTrials.gov NCT01492725

Acknowledging support from:





strokefoundation



neuroscience trials australia


The Royal Australasian College of Physicians Solitaire FR[™] device supplied free of charge by







<u>Ex</u>tending the time for <u>T</u>hrombolysis in <u>E</u>mergency <u>N</u>eurological <u>D</u>eficits







FRIDAY 12 SEPTEMBER 12pm - 4pm

GAMBARO'S FUNCTION CENTRE Caxton St, Petrie Terrace Tickets \$150 each



An 'old-school' networking lunch to raise money for research into Stroke treatment and prevention at Queensland's largest hospital, RBWH.

Hosted by former Wallaby and Stroke survivor Dan Crowley



BOOK NOW phone 07 3646 7588 or visit rbwhfoundation.com.au